Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425)
From MaRDI portal
!
This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use the normal view instead:
scientific article; zbMATH DE number 7616814
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials |
scientific article; zbMATH DE number 7616814 |
Statements
Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (English)
0 references
15 November 2022
0 references
adaptive design
0 references
adaptive randomization
0 references
Bayesian method
0 references
Bayesian adaptive design
0 references
Bayesian optimal interval
0 references
BATTLE trial
0 references
basket trial
0 references
binary endpoint
0 references
biomarker
0 references
BOIN design
0 references
BOP2 design
0 references
cancer trial
0 references
calibration
0 references
clinical trial
0 references
continual reassessment method
0 references
dose finding
0 references
dose-limiting toxicity
0 references
dose escalation
0 references
decision making
0 references
Dirichlet distribution
0 references
early stopping
0 references
efficacy
0 references
efficiency
0 references
futility
0 references
frequentist
0 references
GBM AGILE trial
0 references
I-SPY2 trial
0 references
interim analysis
0 references
immunotherapy
0 references
master protocol
0 references
maximum tolerated dose
0 references
model-assisted design
0 references
molecularly targeted agent
0 references
multinomial endpoint
0 references
multiple outcomes
0 references
optimal design
0 references
operating characteristics
0 references
phase I clinical trial
0 references
phase II clinical trial
0 references
platform trial
0 references
posterior probability
0 references
predictive probability
0 references
randomized trial
0 references
statistical inference
0 references
sequential monitoring
0 references
simulations
0 references
time-to-event endpoint
0 references
toxicity
0 references
umbrella trial
0 references
0 references
0 references
0 references
